688321.SH
微芯生物
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 25.89
−7.37%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.0B | 910.1M | 657.9M | 523.7M | 529.9M |
| Cost of Revenue | 130.4M | 117.2M | 87.5M | 57.0M | 30.0M |
| Gross Profit | 874.4M | 792.8M | 570.5M | 466.7M | 499.9M |
| Operating Expenses | |||||
| R&D Expense | 220.3M | 221.6M | 213.5M | 270.4M | 163.7M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 92.5M | 93.3M | 81.1M | 83.5M | 75.1M |
| Selling & Marketing Expense | 409.9M | 381.2M | 330.8M | 284.4M | 245.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 758.4M | 728.8M | 648.1M | 662.3M | 496.5M |
| Cost and Expenses | 888.9M | 846.0M | 735.5M | 719.3M | 526.5M |
| Operating Income (EBIT) | 97.6M | 50.1M | (178.5M) | 97.1M | 16.0M |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 97.3M | 50.1M | (96.7M) | 97.0M | 15.2M |
| Income Tax Expense | (1.1M) | (906.7K) | 17.9M | 47.8M | 2.3M |
| Bottom Line | |||||
| Net Income | 98.4M | 51.0M | (114.6M) | 88.8M | 17.5M |
| Earnings from Cont. Ops | 98.4M | 51.0M | (114.6M) | 49.2M | 12.8M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 98.4M | 51.0M | (114.6M) | 88.8M | 17.5M |
| Per Share | |||||
| Basic EPS | CN¥0.24 | CN¥0.13 | (CN¥0.28) | CN¥0.22 | CN¥0.04 |
| Diluted EPS | CN¥0.24 | CN¥0.13 | (CN¥0.28) | CN¥0.22 | CN¥0.04 |
| Revenue Per Share | CN¥2.36 | CN¥2.23 | CN¥1.61 | CN¥1.28 | CN¥1.30 |
| Shares | |||||
| Basic Shares Outstanding | 425.8M | 407.7M | 408.0M | 408.3M | 406.6M |
| Diluted Shares Outstanding | 425.8M | 407.7M | 408.0M | 408.3M | 406.6M |
| Profitability Metrics | |||||
| EBITDA | — | 120.7M | (119.4M) | 141.0M | 56.6M |
| D&A | — | 70.6M | 59.1M | 43.9M | 40.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026